WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2024)
Top general drug manufacturer stocks in 2024 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
JNJ
JOHNSON & JOHNSON
United States
$372.17B2,406,679,18368.67%0.19%Net SellingNet Selling
SNY
SANOFI
France
$123.12B1,264,799,96920.28%0.00%
AZN
ASTRAZENECA PLC
United Kingdom
$238.42B1,550,162,62631.27%0.00%
LLY
ELI LILLY & CO
United States
$731.81B950,405,38680.98%11.18%Net SellingNet Selling
NVS
NOVARTIS AG
Switzerland
$209.28B2,040,400,0006.85%0.00%
BIIB
BIOGEN INC
United States
$33.57B145,596,89587.16%2.11%Net SellingNet Selling
GSK
GSK PLC
United Kingdom
$90.95B4,044,000,0007.76%0.00%
ABBV
ABBVIE INC
United States
$293.88B1,765,867,78169.50%0.15%Net SellingNet Selling
MRK
MERCK & CO INC
United States
$332.28B2,532,806,30775.31%0.19%Net BuyingNet Buying
GILD
GILEAD SCIENCES INC
United States
$84.37B1,245,853,20981.78%1.09%Net SellingNet Selling
AMGN
AMGEN INC
United States
$167.62B536,434,69275.31%1.01%Net SellingNet Selling
BMY
BRISTOL MYERS SQUIBB CO
United States
$89.25B2,027,100,09675.02%0.36%Net SellingNet Selling
OGN
ORGANON & CO
United States
$5.61B257,170,72776.68%0.20%Net SellingNet Selling
GRFS
GRIFOLS SA
United States
$5.29B687,554,90819.42%0.00%
PFE
PFIZER INC
United States
$162.29B5,666,592,89865.52%0.27%Net SellingNet Selling
SCLX
SCILEX HOLDING CO
United States
$163.07M181,189,93515.54%34.69%Net BuyingNet Buying
AMRN
AMARIN CORP PLC
Ireland
$357.46M410,868,65921.49%15.40%Net Selling
MIRA
MIRA PHARMACEUTICALS INC
United States
$9.68M14,780,8853.77%30.26%Net Buying

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in May 2024?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Johnson & Johnson (NYSE:JNJ)


Johnson & Johnson (NYSE:JNJ) is the top general drug manufacturer stock with a Zen Score of 60, which is 23 points higher than the general drug manufacturer industry average of 37. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -2.74% over the past year, underperforming other general drug manufacturer stocks by -21 percentage points.

Johnson & Johnson has an average 1 year price target of $176.88, an upside of 14.38% from Johnson & Johnson's current stock price of $154.64.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Johnson & Johnson, 37.5% have issued a Strong Buy rating, 25% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the second best general drug manufacturer stock with a Zen Score of 58, which is 21 points higher than the general drug manufacturer industry average of 37. It passed 20 out of 38 due diligence checks and has strong fundamentals. Sanofi has seen its stock lose -9.35% over the past year, underperforming other general drug manufacturer stocks by -27 percentage points.

Sanofi has an average 1 year price target of $55.00, an upside of 13.01% from Sanofi's current stock price of $48.67.

Sanofi stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Sanofi, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Astrazeneca (NASDAQ:AZN)


Astrazeneca (NASDAQ:AZN) is the third best general drug manufacturer stock with a Zen Score of 49, which is 12 points higher than the general drug manufacturer industry average of 37. It passed 18 out of 38 due diligence checks and has strong fundamentals. Astrazeneca has seen its stock return 2.95% over the past year, underperforming other general drug manufacturer stocks by -15 percentage points.

Astrazeneca has an average 1 year price target of $83.50, an upside of 8.58% from Astrazeneca's current stock price of $76.90.

Astrazeneca stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Astrazeneca, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 8.1%, which is 5 percentage points higher than the general drug manufacturer industry average of 3.56%. Sanofi's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 82.1% indicates that its high dividend yield is sustainable for the long-term.

2. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 5.8%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.56%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of -3,300% indicates that its high dividend yield might not be sustainable for the long-term.

3. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 5.31%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.56%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of -75.7% indicates that its high dividend yield might not be sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.03% in the last day, and up 1.66% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are down.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Biogen has a valuation score of 86, which is 53 points higher than the general drug manufacturer industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -24.71% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -43 percentage points.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 86, which is 53 points higher than the general drug manufacturer industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Sanofi's stock has dropped -9.35% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -27 percentage points.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gsk has a valuation score of 71, which is 38 points higher than the general drug manufacturer industry average of 33. It passed 5 out of 7 valuation due diligence checks.

Gsk's stock has gained 24.46% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 6 percentage points.

Are general drug manufacturer stocks a good buy now?

56.25% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 11.01% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 31.85x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.